AR029611A1 - Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4 - Google Patents

Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4

Info

Publication number
AR029611A1
AR029611A1 ARP000100290A ARP000100290A AR029611A1 AR 029611 A1 AR029611 A1 AR 029611A1 AR P000100290 A ARP000100290 A AR P000100290A AR P000100290 A ARP000100290 A AR P000100290A AR 029611 A1 AR029611 A1 AR 029611A1
Authority
AR
Argentina
Prior art keywords
compounds
vla
inhibit
leucocits
adhesion
Prior art date
Application number
ARP000100290A
Other languages
English (en)
Original Assignee
Elan Pharm Inc
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Wyeth Corp filed Critical Elan Pharm Inc
Publication of AR029611A1 publication Critical patent/AR029611A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se describen compuestos que se adhieren a VLA-4. Algunos de estos compuestos inhiben también la adhesion de leucocitos y, en particular, la adhesion de leucocitos intermediada por VLA-4. Dichos compuestos son utiles para el tratamiento de enfermedades inflamatorias en un paciente mamífero, por ejemplo, en un ser humano, tal como asma, enfermedad de Alzheimer, aterosclerosis, demencia causada por SIDA, diabetes, enfermedades intestinales inflamatorias, artritis reumatoide, trasplantes de tejidos, metástasis de tumores e isquemia de miocardio. Los compuestos pueden administrarse también para el tratamiento de enfermedades cerebrales inflamatorias tales como esclerosis multiple.
ARP000100290A 1999-01-25 2000-01-24 Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4 AR029611A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23747399A 1999-01-25 1999-01-25

Publications (1)

Publication Number Publication Date
AR029611A1 true AR029611A1 (es) 2003-07-10

Family

ID=22893870

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100290A AR029611A1 (es) 1999-01-25 2000-01-24 Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4

Country Status (9)

Country Link
EP (1) EP1150997A1 (es)
JP (1) JP2002539080A (es)
CN (1) CN1185250C (es)
AR (1) AR029611A1 (es)
AU (1) AU3348700A (es)
CA (1) CA2359114A1 (es)
HK (1) HK1044549B (es)
MX (1) MXPA01007394A (es)
WO (1) WO2000043415A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
JP2005022976A (ja) * 2001-07-18 2005-01-27 Ajinomoto Co Inc カルボン酸誘導体
EP1450901A4 (en) 2001-12-10 2005-05-25 Bristol Myers Squibb Co (1-PHENYL-2-HETEROARYL) ETHYL-GUANIDINE COMPOUNDS AS AN INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE
SK50642005A3 (sk) * 2003-01-24 2006-02-02 Elan Pharmaceuticals, Inc. Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
CA2522084A1 (en) 2003-04-10 2004-10-28 Amgen Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
US10906874B2 (en) 2016-09-18 2021-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. YAP1 inhibitors that target the interaction of YAP1 with OCT4
PE20211450A1 (es) 2018-03-14 2021-08-05 H Lee Moffitt Cancer Ct & Res Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1102316A (en) * 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
FR2679903B1 (fr) * 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
AU1354292A (en) * 1991-03-18 1992-10-21 Pentapharm Ag Parasubstituted phenylalanine derivates
DE69530392D1 (de) * 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
EP1017382B1 (en) * 1997-05-29 2006-03-01 Merck & Co., Inc. (a New Jersey corp.) Biarylalkanoic acids as cell adhesion inhibitors
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
NZ502582A (en) * 1997-07-31 2002-07-26 American Home Prod Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4

Also Published As

Publication number Publication date
EP1150997A1 (en) 2001-11-07
AU3348700A (en) 2000-08-07
MXPA01007394A (es) 2002-04-09
WO2000043415A1 (en) 2000-07-27
HK1044549B (zh) 2005-05-27
HK1044549A1 (en) 2002-10-25
JP2002539080A (ja) 2002-11-19
CN1340058A (zh) 2002-03-13
CA2359114A1 (en) 2000-07-27
CN1185250C (zh) 2005-01-19

Similar Documents

Publication Publication Date Title
AR013384A1 (es) Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4
ES2221183T3 (es) Compuestos oxicarbamilo que inhiben la adhesion de leucocitos mediada por vla-4.
BR9812118A (pt) Compostos do tipo 4-amino-fenilalanina que inibem adesão de leucócito mediada por vla-4
BR9811569A (pt) Compostos que inibem a adesão de leucócito mediada por vla-4
BR0007663A (pt) Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
HK1072608A1 (en) Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
BR9811573A (pt) Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4
BR9811594A (pt) Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4
BR9812111A (pt) Dipeptìdeo e compostos correlatos que inibem adesão de leucócito mediada por vla-4
BRPI0513143A (pt) antagonistas de vla-4 multivalentes compreendendo porções poliméricas
AR016387A1 (es) Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos
EA200401561A1 (ru) Гетероарильные соединения, которые ингибируют опосредованную 4-интегринами адгезию лейкоцитов
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
AR029611A1 (es) Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4
AR022405A1 (es) Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos
AR026105A1 (es) Compuetos heteroarilo, heterociclico y ilo que
AR042047A1 (es) Compuestos de heteroarilo que inhiben la adhesion de leucocitos mediada por integrinas alfa 4

Legal Events

Date Code Title Description
FB Suspension of granting procedure